Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964592 | 0.96 | CYP3A4 (0.39) | CYP1A2CYP3A4CYP2C19SMN1; SMN2BLM | |
| SCHEMBL15910098 | 0.91 | CYP3A4 (0.43) | CYP1A2CYP3A4CYP2C19SMN1; SMN2BLM | |
| SCHEMBL16270246 | 0.87 | HDAC1 (0.38) | GAA | |
| SCHEMBL14802570 | 0.87 | POLB (0.33) | SMN1; SMN2L3MBTL1POLBPPARDPPARA | |
| SCHEMBL832556 | 0.87 | CYP3A4 (0.46) | CYP1A2CYP3A4CYP2C19SMN1; SMN2BLM | |
| SCHEMBL9964595 | 0.87 | L3MBTL1 (0.37) | CYP1A2CYP3A4CYP2C19SMN1; SMN2BLM | |
| SCHEMBL16573656 | 0.86 | SERPINE1 (0.35) | CYP1A2CYP3A4CYP2C19SMN1; SMN2TSHR | |
| SCHEMBL11956787 | 0.85 | PRSS1 (0.34) | CYP1A2CYP3A4CYP2C19SMN1; SMN2TSHR | |
| SCHEMBL863376 | 0.85 | L3MBTL1 (0.47) | L3MBTL1GAAPPARDPPARA | |
| SCHEMBL16270523 | 0.84 | MEN1 (0.38) | CYP1A2CYP3A4CYP2C19SMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250374-A1 | Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use | ORTHOCON, INC. | 2016-09-01 | — | — | US | disclosed |
| US-9314547-B2 | Absorbable multi-putty bone cements and hemostatic compositions and methods of use | ABYRX INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160023997-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150080301-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2015-03-19 | — | — | US | disclosed |
| US-8901347-B1 | Absorbable polyurethanes and methods of use thereof | BEZWADA BIOMEDICAL, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140213688-A1 | Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use | ABYRX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080301-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | HPGDS, ITGAM, P4HTM | CYP1A2 830/4885CYP3A4 1429/4885CYP2C19 331/4885 |
| US-20160023997-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | HPGDS, ITGAM, P4HTM | CYP1A2 830/4885CYP3A4 1429/4885CYP2C19 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.